Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TRILAFON vs BYFAVO
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Perphenazine is a typical antipsychotic that blocks postsynaptic dopamine D2 receptors in the brain, exerting antipsychotic effects. It also has alpha-adrenergic blocking, anticholinergic, and antihistaminic properties.
Selective adenosine A2A receptor antagonist; promotes wakefulness by blocking the inhibitory effects of adenosine on arousal-promoting neurons in the brain.
Schizophrenia,Schizoaffective disorder,Severe nausea and vomiting (in adults),Bipolar disorder (off-label)
Improvement of excessive daytime sleepiness in adult patients with obstructive sleep apnea (OSA) as an adjunct to upper airway stimulation therapy
8-16 mg orally twice daily; maximum 64 mg/day. Also 5-10 mg IM every 4-6 hours, maximum 30 mg/day.
For induction and maintenance of general anesthesia: 0.3 mg/kg intravenously over 30 seconds, followed by an infusion of 1.5 mg/kg/hour adjusted to effect. Additional boluses of 0.075 mg/kg may be given as needed.
Terminal elimination half-life is approximately 10–20 hours (mean ~12 hours); supports twice-daily dosing.
Terminal elimination half-life is approximately 2-4 hours; clinical context: requires continuous infusion for sustained effect, as rapid clearance may lead to loss of efficacy.
Extensively metabolized in the liver via glucuronidation, sulfoxidation, side-chain oxidation, and N-dealkylation. CYP2D6 is a major enzyme involved in metabolism; polymorphisms can lead to poor metabolizer status.
Primarily metabolized by CYP3A4 and CYP2D6, with minor contribution from CYP1A2.
Primarily hepatic metabolism; less than 1% excreted unchanged in urine; biliary/fecal elimination of metabolites accounts for the majority of elimination.
Renal excretion accounts for approximately 90% of the administered dose, with <5% as unchanged drug. Biliary/fecal elimination is minimal (<5%).
90–95% bound, primarily to albumin and alpha-1-acid glycoprotein.
Approximately 70-80% bound to human serum albumin and alpha-1-acid glycoprotein.
Approximately 10–15 L/kg; large Vd indicates extensive tissue distribution.
Volume of distribution (Vd) is 0.3-0.5 L/kg; clinical meaning: indicates moderate distribution into tissues, not extensive peripheral sequestration.
Oral: 40–50% (due to first-pass metabolism); IM: 100% (assumed complete absorption).
Bioavailability is not applicable for intravenous formulation; oral bioavailability is negligible due to extensive first-pass metabolism (<5% if administered orally).
No dosage adjustment required for GFR 10-50 m L/min; use 50% of normal dose if GFR <10 m L/min.
No dose adjustment required for mild to moderate renal impairment. For severe renal impairment (e GFR <30 m L/min/1.73 m²), consider reduced infusion rate due to prolonged recovery times; specific dose not established.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use.
Child-Pugh A and B: No adjustment. Child-Pugh C: Reduce infusion rate by 50% and monitor for prolonged sedation; starting infusion at 0.75 mg/kg/hour is recommended.
Not recommended for children under 12 years; for ages 12 and older, 6-12 mg orally 2-3 times daily; maximum 24 mg/day.
Not approved for pediatric patients <18 years of age. Safety and efficacy not established.
Initiate at 4-8 mg orally daily; increase slowly; monitor for QT prolongation, hypotension, and tardive dyskinesia.
For patients ≥65 years, consider lower initial infusion rate (1 mg/kg/hour) and reduce bolus doses; titrate carefully due to increased sensitivity and slower emergence from anesthesia.
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Perphenazine is not approved for the treatment of dementia-related psychosis.
Not recommended for use in patients with severe hepatic impairment (Child-Pugh Class C).
Extrapyramidal symptoms (including tardive dyskinesia) may occur,Neuroleptic malignant syndrome (NMS) - potentially fatal,QT prolongation and risk of arrhythmias,Orthostatic hypotension,Seizures (lower seizure threshold),Leukopenia, neutropenia, and agranulocytosis,Hematologic toxicity,Hyperprolactinemia,Cognitive and motor impairment,Antiemetic effect may mask signs of toxicity or overdose,Use in elderly with dementia not approved
Risk of transient ischemic attacks and seizures; discontinue use if neurological symptoms occur.,May cause dose-related increases in blood pressure and heart rate; monitor cardiovascular status.,Not recommended in patients with unstable cardiovascular disease, recent myocardial infarction, or stroke.,Potential for drug interactions with strong CYP3A4 inhibitors or inducers.,May cause insomnia, anxiety, or restlessness.
Hypersensitivity to perphenazine or any component of the formulation,Comatose states,CNS depression due to alcohol, barbiturates, or other drugs,Subcortical brain damage,Blood dyscrasias,Bone marrow suppression,Severe hypotension,Known QT prolongation or concurrent use with QT-prolonging drugs
Hypersensitivity to BYFAVO or any of its components,Severe hepatic impairment (Child-Pugh Class C)
Avoid grapefruit and grapefruit juice as they may increase perphenazine levels. Limit caffeine intake as it may worsen side effects like restlessness. Taking with food may reduce GI upset but avoid high-fat meals which can affect absorption.
No specific food interactions are reported. However, because sedation may cause nausea, avoid heavy meals immediately before sedation. Grapefruit juice does not significantly interact with remimazolam.
First trimester: Periconceptional use associated with neural tube defects? Limited data; avoid if possible. Second and third trimesters: Risk of extrapyramidal symptoms and/or withdrawal in neonates after late third trimester exposure. Overall, use only if benefit outweighs risk; avoid during organogenesis.
BYFAVO is contraindicated in pregnancy. Animal studies show teratogenicity and embryotoxicity in first trimester. Human data insufficient; risk cannot be excluded in all trimesters. Effective contraception required.
Trilafon (perphenazine) is excreted into human milk in small amounts; M/P ratio unknown. Monitor infant for drowsiness, irritability, or movement disorders. Use with caution during breastfeeding.
No data on presence in human milk, effects on breastfed infant, or milk production. M/P ratio unknown. Due to potential for serious adverse reactions, breastfeeding is not recommended during treatment and for at least 2 weeks after last dose.
No established dose adjustment per se; start at lowest effective dose. Increased plasma volume and metabolism during pregnancy may require dose increases to maintain efficacy; individualize based on response and tolerability.
No pharmacokinetic data in pregnancy; standard dosing is not recommended as drug is contraindicated. If use is unavoidable, no specific dose adjustment guidelines exist; use with extreme caution and consider alternative therapy.
TRILAFON (perphenazine) is a typical antipsychotic with potent antiemetic properties. Monitor for extrapyramidal symptoms (EPS), especially akathisia and dystonia. Avoid use in patients with CNS depression or bone marrow suppression. May lower seizure threshold; use cautiously in epilepsy. QT prolongation risk requires ECG monitoring. Taper dose when discontinuing to avoid withdrawal dyskinesias.
BYFAVO (remimazolam) is an ultra-short-acting benzodiazepine for procedural sedation. Onset within 1-2 minutes, recovery typically within 10 minutes. Flumazenil is the reversal agent. Monitor for respiratory depression; have resuscitation equipment available. Avoid in severe hepatic impairment. Coadministration with opioids increases sedation depth; reduce doses accordingly.
Avoid alcohol and other CNS depressants.,Report any involuntary muscle movements, stiffness, or restlessness immediately.,May cause drowsiness; avoid driving until you know how the medication affects you.,Rise slowly from sitting or lying to prevent dizziness.,Use sun protection as this drug may increase sensitivity to sunlight.,Do not stop taking abruptly without consulting your doctor.,Inform all healthcare providers that you are taking this medication.
You will be closely monitored during the procedure. Do not drive, operate machinery, or make important decisions for at least 24 hours after receiving this medication.,Inform your healthcare provider if you have a history of liver disease, glaucoma, or substance abuse.,Do not consume alcohol for at least 24 hours after sedation.,You may experience temporary memory loss or drowsiness; arrange for a responsible adult to accompany you home.,Report any unusual side effects such as prolonged drowsiness, difficulty breathing, or allergic reactions (rash, swelling) to your doctor immediately.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TRILAFON vs BYFAVO, answered by our medical review team.
TRILAFON is a Phenothiazine Antipsychotic that works by Perphenazine is a typical antipsychotic that blocks postsynaptic dopamine D2 receptors in the brain, exerting antipsychotic effects. It also has alpha-adrenergic blocking, anticholinergic, and antihistaminic properties.. BYFAVO is a Benzodiazepine that works by Selective adenosine A2A receptor antagonist; promotes wakefulness by blocking the inhibitory effects of adenosine on arousal-promoting neurons in the brain.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TRILAFON and BYFAVO depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TRILAFON is: 8-16 mg orally twice daily; maximum 64 mg/day. Also 5-10 mg IM every 4-6 hours, maximum 30 mg/day.. The standard adult dose of BYFAVO is: For induction and maintenance of general anesthesia: 0.3 mg/kg intravenously over 30 seconds, followed by an infusion of 1.5 mg/kg/hour adjusted to effect. Additional boluses of 0.075 mg/kg may be given as needed.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TRILAFON and BYFAVO in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TRILAFON is classified as Category C. First trimester: Periconceptional use associated with neural tube defects? Limited data; avoid if possible. Second and third trimesters: Risk of extrapyramidal symptoms and/or with. BYFAVO is classified as Category C. BYFAVO is contraindicated in pregnancy. Animal studies show teratogenicity and embryotoxicity in first trimester. Human data insufficient; risk cannot be excluded in all trimesters. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.